Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025
Client: SCIENTIFIC SYSTEMS COMPANY, INC. · Firm: CARDINAL POINT PARTNERS
Naval aviation technology issues in the National Defense Authorization Acts for FY2025 (H.R. 8070).
Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025
Client: SCIENTIFIC SYSTEMS COMPANY, INC. · Firm: CARDINAL POINT PARTNERS
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
SCIENTIFIC SYSTEMS COMPANY, INC. via CARDINAL POINT PARTNERS
2024 · fourth_quarter · Q4
Air Force research and development of navigation technologies and Navy aviation technologies in the Defense Appropriations Act for FY2025 (H.R. 8774, S. 4942).
Filing targets: SENATE
SCIENTIFIC SYSTEMS COMPANY, INC. via CARDINAL POINT PARTNERS
2024 · third_quarter · Q3
Source: Senate LDA
| SCHOTT NORTH AMERICA |
| 19 |
| 2008–2012 |
| BEACON POWER CORPORATION | 15 | 2009–2011 |
| KNOWLEDGE SHARING SYSTEMS | 13 | 2007–2010 |
| AVUE TECHNOLOGIES CORP | 12 | 2007–2010 |
| ALION SCIENCE AND TECHNOLOGY | 11 | 2007–2009 |
| KIT BOND STRATEGIES ON BEHALF OF THE HAWTHORN FOUNDATION | 11 | 2013–2015 |
| GOODRICH CORPORATION | 10 | 2009–2011 |
| ICONIC HEALTH LLC | 9 | 2008–2009 |
| MIDDLESEX COMMUNITY COLLEGE FOUNDATION | 9 | 2011–2013 |
| EHARMONY | 8 | 2007–2008 |
| LIFE TECHNOLOGIES CORPORATION | 8 | 2009–2011 |
| BIGBELLY SOLAR | 6 | 2009 |
| CROSSLINK | 6 | 2010–2012 |
| HARRIS CORPORATION | 5 | 2007–2009 |
| LANGUAGE LINE | 5 | 2009–2010 |
| AHURA SCIENTIFIC INC | 4 | 2009 |
| ALLEN-VANGUARD CORPORATION | 4 | 2009–2010 |
| MISSOURI HOSPITAL ASSOCIATION | 4 | 2006–2008 |
| PARTNERS HEALTHCARE | 4 | 2009–2010 |
| CAMBRIDGE COLLEGE | 3 | 2007 |
| JUNIPER NETWORKS | 2 | 2006 |
| MISSOURI BIOTECHNOLOGY ASSOCIATION | 2 | 2008 |
| VUANCE | 2 | 2007 |
| BRIGHTON MARINE, INC. | 1 | 2024 |
Naval aviation technology issues in the National Defense Authorization Acts for FY2025 (H.R. 8070).
Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Biodefense research in the National Defense Authorization Act for FY2025 (H.R. 8070 and S. 4638)
Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Biodefense research in the National Defense Authorization Act for FY2025 (H.R. 8070 and S. 4638)
Department of Defense Appropriations Act, 2025
Client: GENERAL ELECTRIC COMPANY · Firm: CARDINAL POINT PARTNERS
Air Force research and development on manufacturing for aircraft sustainment in the Defense Appropriations Act for FY2025 (H.R. 8774)
Department of Defense Appropriations Act, 2025
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2025 (H.R. 8774, S. 4921) National Institutes of Health research on Long COVID in the Labor-HHS Appropriations Act for FY2025 National Institutes of Health research on cocaine abuse treatments in the Labor-HHS Appropriations Act for FY2025 (H.R. 9029, S. 4942)
Department of Defense Appropriations Act, 2025
Client: SCIENTIFIC SYSTEMS COMPANY, INC. · Firm: CARDINAL POINT PARTNERS
Air Force research and development of navigation technologies and Navy aviation technologies in the Defense Appropriations Act for FY2025 (H.R. 8774, S. 4942).
Department of Defense Appropriations Act, 2025
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2025 (H.R. 8774) National Institutes of Health research on Long COVID in the Labor-HHS Appropriations Act for FY2025 (No bill numbers) National Institutes of Health research on cocaine abuse treatments in the Labor-HHS Appropriations Act for FY2025 (No bill numbers)
Department of Defense Appropriations Act, 2025
Client: SCIENTIFIC SYSTEMS COMPANY, INC. · Firm: CARDINAL POINT PARTNERS
Air Force research and development of navigation technologies and Navy aviation technologies in the Defense Appropriations Act for FY2025 (H.R. 8774).
Department of Defense Appropriations Act, 2025
Client: GENERAL ELECTRIC COMPANY · Firm: CARDINAL POINT PARTNERS
Air Force research and development on manufacturing for aircraft sustainment in the Defense Appropriations Act for FY2025 (H.R. 8774)
Department of Defense Appropriations Act, 2025
Client: SCIENTIFIC SYSTEMS COMPANY, INC. · Firm: CARDINAL POINT PARTNERS
Air Force research and development of navigation technologies and Navy aviation technologies in the Defense Appropriations Act for FY2025 (H.R. 8774, S. 4942).
Department of Defense Appropriations Act, 2025
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2025 (H.R. 8774, S. 4921) National Institutes of Health research on Long COVID in the Labor-HHS Appropriations Act for FY2025 National Institutes of Health research on cocaine abuse treatments in the Labor-HHS Appropriations Act for FY2025 (H.R. 9029, S. 4942)
Department of Defense Appropriations Act, 2025
Client: GENERAL ELECTRIC COMPANY · Firm: CARDINAL POINT PARTNERS
Air Force research and development on manufacturing for aircraft sustainment in the Defense Appropriations Act for FY2025 (H.R. 8774)
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2025 (H.R. 8774, S. 4921) National Institutes of Health research on Long COVID in the Labor-HHS Appropriations Act for FY2025 National Institutes of Health research on cocaine abuse treatments in the Labor-HHS Appropriations Act for FY2025 (H.R. 9029, S. 4942)
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2025 (H.R. 8774, S. 4921) National Institutes of Health research on Long COVID in the Labor-HHS Appropriations Act for FY2025 National Institutes of Health research on cocaine abuse treatments in the Labor-HHS Appropriations Act for FY2025 (H.R. 9029, S. 4942)
Pandemic and All-Hazards Preparedness and Response Act
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Medical Countermeasures research, development and acquisition in the Pandemic All-Hazards Preparedness and Response Act (S. 2333).
Pandemic and All-Hazards Preparedness and Response Act
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Medical Countermeasures research, development and acquisition in the Pandemic All-Hazards Preparedness and Response Act (S. 2333).
Pandemic and All-Hazards Preparedness and Response Act
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Medical Countermeasures research, development and acquisition in the Pandemic All-Hazards Preparedness and Response Act (S. 2333).
National Defense Authorization Act for Fiscal Year 2025
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Biodefense research in the National Defense Authorization Act for FY2025 (H.R. 8070 and S. 4638)
National Defense Authorization Act for Fiscal Year 2025
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Biodefense research in the National Defense Authorization Act for FY2025 (H.R. 8070 and S. 4638)
Department of Defense Appropriations Act, 2025
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2025 (H.R. 8774, S. 4921) National Institutes of Health research on Long COVID in the Labor-HHS Appropriations Act for FY2025 National Institutes of Health research on cocaine abuse treatments in the Labor-HHS Appropriations Act for FY2025 (H.R. 9029, S. 4942)
Department of Defense Appropriations Act, 2025
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2025 (H.R. 8774, S. 4921) National Institutes of Health research on Long COVID in the Labor-HHS Appropriations Act for FY2025 National Institutes of Health research on cocaine abuse treatments in the Labor-HHS Appropriations Act for FY2025 (H.R. 9029, S. 4942)
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: SCIENTIFIC SYSTEMS COMPANY, INC. · Firm: CARDINAL POINT PARTNERS
Air Force research and development of navigation technologies and Navy aviation technologies in the Defense Appropriations Act for FY2025 (H.R. 8774, S. 4942).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2025 (H.R. 8774, S. 4921) National Institutes of Health research on Long COVID in the Labor-HHS Appropriations Act for FY2025 National Institutes of Health research on cocaine abuse treatments in the Labor-HHS Appropriations Act for FY2025 (H.R. 9029, S. 4942)
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: SCIENTIFIC SYSTEMS COMPANY, INC. · Firm: CARDINAL POINT PARTNERS
Air Force research and development of navigation technologies and Navy aviation technologies in the Defense Appropriations Act for FY2025 (H.R. 8774, S. 4942).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2025 (H.R. 8774, S. 4921) National Institutes of Health research on Long COVID in the Labor-HHS Appropriations Act for FY2025 National Institutes of Health research on cocaine abuse treatments in the Labor-HHS Appropriations Act for FY2025 (H.R. 9029, S. 4942)
National Defense Authorization Act for Fiscal Year 2024
Client: ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE · Firm: CARDINAL POINT PARTNERS
Military healthcare issues in the National Defense Authorization Act for FY2024 (S. 2226, H.R. 2670)
National Defense Authorization Act for Fiscal Year 2024
Client: ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE · Firm: CARDINAL POINT PARTNERS
Military healthcare issues in the National Defense Authorization Act for FY2024 (S. 2226, H.R. 2670)
National Defense Authorization Act for Fiscal Year 2024
Client: GENERAL ELECTRIC COMPANY · Firm: CARDINAL POINT PARTNERS
Air Force research and development on manufacturing for aircraft sustainment and hypersonics in the National Defense Authorization Act for FY2024 (H.R. 2670, S. 2226).
National Defense Authorization Act for Fiscal Year 2024
Client: GENERAL ELECTRIC COMPANY · Firm: CARDINAL POINT PARTNERS
Air Force research and development on manufacturing for aircraft sustainment and hypersonics in the National Defense Authorization Act for FY2024 (H.R. 2670, S. 2226).
Department of Defense Appropriations Act, 2024
Client: SCIENTIFIC SYSTEMS COMPANY, INC. · Firm: CARDINAL POINT PARTNERS
Air Force research and development of navigation technologies and research and development on Navy unmanned aerial vehicles in the Defense Appropriations Act for FY2024 (H.R. 4365, S. 2587).
Department of Defense Appropriations Act, 2024
Client: SCIENTIFIC SYSTEMS COMPANY, INC. · Firm: CARDINAL POINT PARTNERS
Air Force research and development of navigation technologies in the Defense Appropriations Act for FY2024 (H.R. 4365, S. 2587).
Department of Defense Appropriations Act, 2024
Client: GENERAL ELECTRIC COMPANY · Firm: CARDINAL POINT PARTNERS
Air Force research and development on manufacturing for aircraft sustainment and hypersonics in the Defense Appropriations Act for FY2024 (H.R. 4365).
Department of Defense Appropriations Act, 2024
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2024 (H.R. 4365, S. 2587)
Department of Defense Appropriations Act, 2024
Client: GENERAL ELECTRIC COMPANY · Firm: CARDINAL POINT PARTNERS
Air Force research and development on manufacturing for aircraft sustainment and hypersonics in the Defense Appropriations Act for FY2024 (H.R. 4365, S. 2587).
Department of Defense Appropriations Act, 2024
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2024 (H.R. 4365, S. 2587)
Department of Defense Appropriations Act, 2024
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2024 (H.R. 4365)
Department of Defense Appropriations Act, 2024
Client: SCIENTIFIC SYSTEMS COMPANY, INC. · Firm: CARDINAL POINT PARTNERS
Air Force research and development of navigation technologies and research and development on Navy unmanned aerial vehicles in the Defense Appropriations Act for FY2024 (H.R. 4365).
Department of Defense Appropriations Act, 2024
Client: GENERAL ELECTRIC COMPANY · Firm: CARDINAL POINT PARTNERS
Air Force research and development on manufacturing for aircraft sustainment and hypersonics in the Defense Appropriations Act for FY2024 (H.R. 4365, S. 2587).
National Defense Authorization Act for Fiscal Year 2024
Client: GENERAL ELECTRIC COMPANY · Firm: CARDINAL POINT PARTNERS
Air Force research and development on manufacturing for aircraft sustainment and hypersonics in the National Defense Authorization Act for FY2024 (H.R. 2670, S. 2226).
National Defense Authorization Act for Fiscal Year 2024
Client: ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE · Firm: CARDINAL POINT PARTNERS
Military healthcare issues in the National Defense Authorization Act for FY2024 (S. 2226, H.R. 2670)
National Defense Authorization Act for Fiscal Year 2024
Client: ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE · Firm: CARDINAL POINT PARTNERS
Military healthcare issues in the National Defense Authorization Act for FY2024 (S. 2226, H.R. 2670)
National Defense Authorization Act for Fiscal Year 2024
Client: GENERAL ELECTRIC COMPANY · Firm: CARDINAL POINT PARTNERS
Air Force research and development on manufacturing for aircraft sustainment and hypersonics in the National Defense Authorization Act for FY2024 (H.R. 2670, S. 2226).
Department of Defense Appropriations Act, 2024
Client: SCIENTIFIC SYSTEMS COMPANY, INC. · Firm: CARDINAL POINT PARTNERS
Air Force research and development of navigation technologies and research and development on Navy unmanned aerial vehicles in the Defense Appropriations Act for FY2024 (H.R. 4365, S. 2587).
Department of Defense Appropriations Act, 2024
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2024 (H.R. 4365, S. 2587)
Department of Defense Appropriations Act, 2024
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2024 (H.R. 4365, S. 2587)
Department of Defense Appropriations Act, 2024
Client: SCIENTIFIC SYSTEMS COMPANY, INC. · Firm: CARDINAL POINT PARTNERS
Air Force research and development of navigation technologies in the Defense Appropriations Act for FY2024 (H.R. 4365, S. 2587).
Department of Defense Appropriations Act, 2024
Client: GENERAL ELECTRIC COMPANY · Firm: CARDINAL POINT PARTNERS
Air Force research and development on manufacturing for aircraft sustainment and hypersonics in the Defense Appropriations Act for FY2024 (H.R. 4365, S. 2587).
Department of Defense Appropriations Act, 2024
Client: GENERAL ELECTRIC COMPANY · Firm: CARDINAL POINT PARTNERS
Air Force research and development on manufacturing for aircraft sustainment and hypersonics in the Defense Appropriations Act for FY2024 (H.R. 4365, S. 2587).
Consolidated Appropriations Act, 2023
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Proposed legislation on research and development into medical countermeasures for pandemic response and biosecurity in the PREVENT Pandemics Act S.3799 and the FY2023 Consolidated Appropriations Act (H.R. 2617).
Consolidated Appropriations Act, 2023
Client: SCIENTIFIC SYSTEMS COMPANY, INC. · Firm: CARDINAL POINT PARTNERS
Air Force RDTE funding and Navy RDTE funding for aircraft navigation technologies in the Defense Appropriations Act for FY 2023 (H.R. 8236) and the Consolidated Appropriations Act, FY2023 (H.R. 2617).
Consolidated Appropriations Act, 2023
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Advocating for expanded funding for advanced development of COVID vaccines in the Labor-HHS-Education Appropriations Act for FY 2023 (H.R. 8295) and the Consolidated Appropriations Act, FY2023 (H.R. 2617). Advocating for expanded funding for Defense Department research and development on biodefense vaccines in the Defense Appropriations Act for FY 2023 (H.R. 8236) and the Consolidated Appropriations Act, FY2023 (H.R. 2617).
National Defense Authorization Act for Fiscal Year 2022
Client: SCIENTIFIC SYSTEMS COMPANY, INC. · Firm: CARDINAL POINT PARTNERS
Air Force RDTE funding for navigation technologies in the National Defense Authorization Act for FY2022 (H.R. 4350) and the National Defense Authorization Act for FY2023 (no bill introduced).
Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022
Client: GENERAL ELECTRIC COMPANY · Firm: CARDINAL POINT PARTNERS
Air Force research and development and Defense-wide research and development in the Consolidated Appropriations Act for FY2022 (H.R. 4502)
Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022
Client: SCIENTIFIC SYSTEMS COMPANY, INC. · Firm: CARDINAL POINT PARTNERS
Air Force RDTE funding and Navy RDTE funding for aircraft navigation technologies in the Consolidated Appropriations Act for FY2022 (H.R. 4502) and the Defense Appropriations Act for FY 2023 (no bill introduced).
Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Advocating for expanded funding for advanced development of COVID vaccines in Coronavirus Supplemental Appropriations Act (HR925) and the Labor-HHS-Education Appropriations Act for FY 2023 (H.R. 4502 and S. 3062) Advocating for expanded funding for Defense Department research and development on biodefense vaccines in the Defense Appropriations Act for FY 2023 (no bills introduced).
James M. Inhofe National Defense Authorization Act for Fiscal Year 2023
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Advocating for increased funding for research and development on biodefense vaccines in the National Defense Authorization Act for FY2023 (H.R. 7900, S. 4543, H.R. 7776)
James M. Inhofe National Defense Authorization Act for Fiscal Year 2023
Client: SCIENTIFIC SYSTEMS COMPANY, INC. · Firm: CARDINAL POINT PARTNERS
Air Force RDTE funding for navigation technologies in the National Defense Authorization Act for FY2023 H.R. 7900, S. 4543, H.R. 7776.
James M. Inhofe National Defense Authorization Act for Fiscal Year 2023
Client: ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE · Firm: CARDINAL POINT PARTNERS
Military healthcare issues in the National Defense Authorization Act, FY2023 (HR 7776)
National Defense Authorization Act for Fiscal Year 2023
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Advocating for increased funding for research and development on biodefense vaccines in the National Defense Authorization Act for FY2023 (H.R. 7900, S. 4543).
National Defense Authorization Act for Fiscal Year 2023
Client: ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE · Firm: CARDINAL POINT PARTNERS
Military healthcare issues in the National Defense Authorization Act, FY2023 (HR 7900)
National Defense Authorization Act for Fiscal Year 2023
Client: ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE · Firm: CARDINAL POINT PARTNERS
Military healthcare issues in the National Defense Authorization Act, FY2023 (HR 7900, S.4543)
National Defense Authorization Act for Fiscal Year 2023
Client: SCIENTIFIC SYSTEMS COMPANY, INC. · Firm: CARDINAL POINT PARTNERS
Air Force RDTE funding for navigation technologies in the National Defense Authorization Act for FY2023 H.R. 7900, S. 4543, H.R. 7776.
National Defense Authorization Act for Fiscal Year 2023
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Advocating for increased funding for research and development on biodefense vaccines in the National Defense Authorization Act for FY2023 (H.R. 7900).
National Defense Authorization Act for Fiscal Year 2023
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Advocating for increased funding for research and development on biodefense vaccines in the National Defense Authorization Act for FY2023 (H.R. 7900, S. 4543, H.R. 7776)
Department of Defense Appropriations Act, 2023
Client: SCIENTIFIC SYSTEMS COMPANY, INC. · Firm: CARDINAL POINT PARTNERS
Air Force RDTE funding and Navy RDTE funding for aircraft navigation technologies in the Defense Appropriations Act for FY 2023 (H.R. 8236) and the Consolidated Appropriations Act, FY2023 (H.R. 2617).
Department of Defense Appropriations Act, 2023
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Advocating for expanded funding for advanced development of COVID vaccines in the Labor-HHS-Education Appropriations Act for FY 2023 (H.R. 8295) and the Consolidated Appropriations Act, FY2023 (H.R. 2617). Advocating for expanded funding for Defense Department research and development on biodefense vaccines in the Defense Appropriations Act for FY 2023 (H.R. 8236) and the Consolidated Appropriations Act, FY2023 (H.R. 2617).
Department of Defense Appropriations Act, 2023
Client: SCIENTIFIC SYSTEMS COMPANY, INC. · Firm: CARDINAL POINT PARTNERS
Air Force RDTE funding and Navy RDTE funding for aircraft navigation technologies in the Defense Appropriations Act for FY 2023 (H.R. 8236).
Department of Defense Appropriations Act, 2023
Client: GENERAL ELECTRIC COMPANY · Firm: CARDINAL POINT PARTNERS
Navy RDTE funding in the Defense Appropriations Act for FY 2023 (H.R. 8236)
Department of Defense Appropriations Act, 2023
Client: GENERAL ELECTRIC COMPANY · Firm: CARDINAL POINT PARTNERS
Navy RDTE funding in the Defense Appropriations Act for FY 2023 (H.R. 8236)
Department of Defense Appropriations Act, 2023
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Advocating for expanded funding for advanced development of COVID vaccines in the Labor-HHS-Education Appropriations Act for FY 2023 (H.R. 8295) Advocating for expanded funding for Defense Department research and development on biodefense vaccines in the Defense Appropriations Act for FY 2023 (H.R. 8236).
Department of Defense Appropriations Act, 2023
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Advocating for expanded funding for advanced development of COVID vaccines in the Labor-HHS-Education Appropriations Act for FY 2023 (H.R. 8295) Advocating for expanded funding for Defense Department research and development on biodefense vaccines in the Defense Appropriations Act for FY 2023 (H.R. 8236).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Advocating for expanded funding for advanced development of COVID vaccines in the Labor-HHS-Education Appropriations Act for FY 2023 (H.R. 8295) and the Consolidated Appropriations Act, FY2023 (H.R. 2617). Advocating for expanded funding for Defense Department research and development on biodefense vaccines in the Defense Appropriations Act for FY 2023 (H.R. 8236) and the Consolidated Appropriations Act, FY2023 (H.R. 2617).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Advocating for expanded funding for advanced development of COVID vaccines in the Labor-HHS-Education Appropriations Act for FY 2023 (H.R. 8295) Advocating for expanded funding for Defense Department research and development on biodefense vaccines in the Defense Appropriations Act for FY 2023 (H.R. 8236).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Advocating for expanded funding for advanced development of COVID vaccines in the Labor-HHS-Education Appropriations Act for FY 2023 (H.R. 8295) Advocating for expanded funding for Defense Department research and development on biodefense vaccines in the Defense Appropriations Act for FY 2023 (H.R. 8236).
Advocating for expanded funding for advanced development of COVID vaccines in Coronavirus Supplemental Appropriations Act (HR925) and the Labor-HHS-Education Appropriations Act for FY 2023 (H.R. 4502 and S. 3062) Advocating for expanded funding for Defense Department research and development on biodefense vaccines in the Defense Appropriations Act for FY 2023 (no bills introduced).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2022
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Advocating for expanded funding for advanced development of COVID vaccines in Coronavirus Supplemental Appropriations Act (HR925) and the Labor-HHS-Education Appropriations Act for FY 2023 (H.R. 4502 and S. 3062) Advocating for expanded funding for Defense Department research and development on biodefense vaccines in the Defense Appropriations Act for FY 2023 (no bills introduced).
Proposed legislation on research and development into medical countermeasures for pandemic response and biosecurity under consideration by the Senate HELP (PREVENT Pandemics Act S.3799) House Energy and Commerce Committees (no bills introduced).
Proposed legislation on research and development into medical countermeasures for pandemic response and biosecurity under consideration by the Senate HELP (PREVENT Pandemics Act S.3799) House Energy and Commerce Committees (no bills introduced).
Proposed legislation on research and development into medical countermeasures for pandemic response and biosecurity in the PREVENT Pandemics Act S.3799 and the FY2023 Consolidated Appropriations Act (H.R. 2617).
Proposed legislation on research and development into medical countermeasures for pandemic response and biosecurity under consideration by the Senate HELP (PREVENT Pandemics Act S.3799) House Energy and Commerce Committees (no bills introduced).
James M. Inhofe National Defense Authorization Act for Fiscal Year 2023
Client: SCIENTIFIC SYSTEMS COMPANY, INC. · Firm: CARDINAL POINT PARTNERS
Air Force RDTE funding for navigation technologies in the National Defense Authorization Act for FY2023 (S. 4543).
James M. Inhofe National Defense Authorization Act for Fiscal Year 2023
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Advocating for increased funding for research and development on biodefense vaccines in the National Defense Authorization Act for FY2023 (H.R. 7900, S. 4543).
James M. Inhofe National Defense Authorization Act for Fiscal Year 2023
Client: SCIENTIFIC SYSTEMS COMPANY, INC. · Firm: CARDINAL POINT PARTNERS
Air Force RDTE funding for navigation technologies in the National Defense Authorization Act for FY2023 H.R. 7900, S. 4543, H.R. 7776.
James M. Inhofe National Defense Authorization Act for Fiscal Year 2023
Client: ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE · Firm: CARDINAL POINT PARTNERS
Military healthcare issues in the National Defense Authorization Act, FY2023 (HR 7900, S.4543)
James M. Inhofe National Defense Authorization Act for Fiscal Year 2023
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Advocating for increased funding for research and development on biodefense vaccines in the National Defense Authorization Act for FY2023 (H.R. 7900, S. 4543, H.R. 7776)
Funding for pandemic response research and development funding in HR 1219 The American Rescue Plan Act of 2021
Combating Global Corruption Act of 2021
Client: GENERAL ELECTRIC COMPANY · Firm: CARDINAL POINT PARTNERS
Air Force research and development in the Defense Appropriations Act for FY2022 (HR 4322) Defense-wide research and development in the Defense Appropriations Act for FY2022 (HR 4322)
Combating Global Corruption Act of 2021
Client: GENERAL ELECTRIC COMPANY · Firm: CARDINAL POINT PARTNERS
Air Force research and development in the Defense Appropriations Act for FY2022 (HR 4322) Defense-wide research and development in the Defense Appropriations Act for FY2022 (HR 4322)
Combating Global Corruption Act of 2021
Client: GENERAL ELECTRIC COMPANY · Firm: CARDINAL POINT PARTNERS
Air Force research and development in the Defense Appropriations Act for FY2022 (HR 4322) Defense-wide research and development in the Defense Appropriations Act for FY2022 (HR 4322)
Combating Global Corruption Act of 2021
Client: GENERAL ELECTRIC COMPANY · Firm: CARDINAL POINT PARTNERS
Air Force research and development in the Defense Appropriations Act for FY2022 (HR 4322) Defense-wide research and development in the Defense Appropriations Act for FY2022 (HR 4322)
National Defense Authorization Act for Fiscal Year 2022
Client: ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE · Firm: CARDINAL POINT PARTNERS
Military healthcare issues in the National Defense Authorization Act, FY2022 (HR 4350, S. 2792)
National Defense Authorization Act for Fiscal Year 2022
Client: SCIENTIFIC SYSTEMS COMPANY, INC. · Firm: CARDINAL POINT PARTNERS
Air Force RDTE funding for navigation technologies in the National Defense Authorization Act for FY2022 (H.R. 4350 and S. 1605).
National Defense Authorization Act for Fiscal Year 2022
Client: SCIENTIFIC SYSTEMS COMPANY, INC. · Firm: CARDINAL POINT PARTNERS
Air Force RDTE funding for navigation technologies in the National Defense Authorization Act for FY2022 (H.R. 4350 and S. 1605).
National Defense Authorization Act for Fiscal Year 2022
Client: ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE · Firm: CARDINAL POINT PARTNERS
Military healthcare issues in the National Defense Authorization Act, FY2022 (HR 4350, S. 2792)
Department of Defense Appropriations Act, 2022
Client: GENERAL ELECTRIC COMPANY · Firm: CARDINAL POINT PARTNERS
Air Force research and development and Defense-wide research and development in the Defense Appropriations Act for FY2022 (HR4432, S. 3023).
Department of Defense Appropriations Act, 2022
Client: SCIENTIFIC SYSTEMS COMPANY, INC. · Firm: CARDINAL POINT PARTNERS
Air Force RDTE funding and Navy RDTE funding for aircraft navigation technologies in the Department of Defense Appropriations Act, FY2022(H.R. 4432, S. 3023).
Department of Defense Appropriations Act, 2022
Client: SCIENTIFIC SYSTEMS COMPANY, INC. · Firm: CARDINAL POINT PARTNERS
Air Force RDTE funding and Navy RDTE funding for aircraft navigation technologies in the Department of Defense Appropriations Act, FY2022(H.R. 4432, S. 3023).
Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Advocating for expanded funding for advanced development of COVID vaccines in Coronavirus Supplemental Appropriations Act (HR925) and the Labor-HHS-Education Appropriations Act for FY 2023 (H.R. 4502 and S. 3062)
Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022
Client: TONIX PHARMACEUTICALS, INC. · Firm: CARDINAL POINT PARTNERS
Advocating for expanded funding for advanced development of COVID vaccines in Coronavirus Supplemental Appropriations Act (HR925) and the Labor-HHS-Education Appropriations Act for FY 2023 (H.R. 4502 and S. 3062)
Air Force research and development of navigation technologies and Navy aviation technologies in the Defense Appropriations Act for FY2025 (H.R. 8774, S. 4942).
Naval aviation technology issues in the National Defense Authorization Acts for FY2025 (H.R. 8070).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TONIX PHARMACEUTICALS, INC. via CARDINAL POINT PARTNERS
2024 · fourth_quarter · Q4
Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2025 (H.R. 8774, S. 4921) National Institutes of Health research on Long COVID in the Labor-HHS Appropriations Act for FY2025 National Institutes of Health research on cocaine abuse treatments in the Labor-HHS Appropriations Act for FY2025 (H.R. 9029, S. 4942)
Medical Countermeasures research, development and acquisition in the Pandemic All-Hazards Preparedness and Response Act (S. 2333).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TONIX PHARMACEUTICALS, INC. via CARDINAL POINT PARTNERS
2024 · third_quarter · Q3
Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2025 (H.R. 8774, S. 4921) National Institutes of Health research on Long COVID in the Labor-HHS Appropriations Act for FY2025 National Institutes of Health research on cocaine abuse treatments in the Labor-HHS Appropriations Act for FY2025 (H.R. 9029, S. 4942)
Medical Countermeasures research, development and acquisition in the Pandemic All-Hazards Preparedness and Response Act (S. 2333).
Biodefense research in the National Defense Authorization Act for FY2025 (H.R. 8070 and S. 4638)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENERAL ELECTRIC COMPANY via CARDINAL POINT PARTNERS
2024 · fourth_quarter · Q4
Air Force research and development on manufacturing for aircraft sustainment in the Defense Appropriations Act for FY2025 (H.R. 8774)
Filing targets: SENATE
GENERAL ELECTRIC COMPANY via CARDINAL POINT PARTNERS
2024 · third_quarter · Q3
Air Force research and development on manufacturing for aircraft sustainment in the Defense Appropriations Act for FY2025 (H.R. 8774)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SCIENTIFIC SYSTEMS COMPANY, INC. via CARDINAL POINT PARTNERS
2024 · second_quarter · Q2
Naval aviation technology issues in the National Defense Authorization Acts for FY2025 (H.R. 8070).
Air Force research and development of navigation technologies and Navy aviation technologies in the Defense Appropriations Act for FY2025 (H.R. 8774).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TONIX PHARMACEUTICALS, INC. via CARDINAL POINT PARTNERS
2024 · second_quarter · Q2
Biodefense research in the National Defense Authorization Act for FY2025 (H.R. 8070 and S. 4638)
Medical Countermeasures research, development and acquisition in the Pandemic All-Hazards Preparedness and Response Act (S. 2333).
Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2025 (H.R. 8774) National Institutes of Health research on Long COVID in the Labor-HHS Appropriations Act for FY2025 (No bill numbers) National Institutes of Health research on cocaine abuse treatments in the Labor-HHS Appropriations Act for FY2025 (No bill numbers)
GENERAL ELECTRIC COMPANY via CARDINAL POINT PARTNERS
2024 · second_quarter · Q2
Air Force research and development on manufacturing for aircraft sustainment in the Defense Appropriations Act for FY2025 (H.R. 8774)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRIGHTON MARINE, INC. via CARDINAL POINT PARTNERS
2024 · second_quarter · RR
Military health care with the TRICARE program Veterans services
Military health care with the TRICARE program Veterans services
TONIX PHARMACEUTICALS, INC. via CARDINAL POINT PARTNERS
2024 · first_quarter · Q1
Biodefense research in the National Defense Authorization Act for FY2025 (no bill numbers)
Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2025 National Institutes of Health research on Long COVID National Institutes of Health research on cocaine abuse treatments
Medical Countermeasures research, development and acquisition in the Pandemic All-Hazards Preparedness Act reauthorization (no bill numbers).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE via CARDINAL POINT PARTNERS
2024 · first_quarter · Q1
Military healthcare issues related to the National Defense Authorization Act for FY2025 (no bill numbers)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SCIENTIFIC SYSTEMS COMPANY, INC. via CARDINAL POINT PARTNERS
2024 · first_quarter · Q1
Air Force research and development of navigation technologies and Navy aviation technologies in the Defense Appropriations Act for FY2025 (No bill numbers).
Naval aviation technology issues in the National Defense Authorization Acts for FY2025 (no bill numbers).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERAL ELECTRIC COMPANY via CARDINAL POINT PARTNERS
2024 · first_quarter · Q1
Air Force research and development on manufacturing for aircraft and automotive sustainment in the National Defense Authorization Act for FY2025
Air Force research and development on manufacturing for aircraft sustainment in the Defense Appropriations Act for FY2025 (no bill numbers).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SCIENTIFIC SYSTEMS COMPANY, INC. via CARDINAL POINT PARTNERS
2023 · fourth_quarter · Q4
Air Force research and development of navigation technologies in the Defense Appropriations Act for FY2024 (H.R. 4365, S. 2587).
Filing targets: SENATE
TONIX PHARMACEUTICALS, INC. via CARDINAL POINT PARTNERS
2023 · fourth_quarter · Q4
Medical Countermeasures research, development and acquisition in the Pandemic All-Hazards Preparedness Act reauthorization (no bill numbers).
Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2024 (H.R. 4365, S. 2587)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENERAL ELECTRIC COMPANY via CARDINAL POINT PARTNERS
2023 · fourth_quarter · Q4
Air Force research and development on manufacturing for aircraft sustainment and hypersonics in the Defense Appropriations Act for FY2024 (H.R. 4365, S. 2587).
Air Force research and development on manufacturing for aircraft sustainment and hypersonics in the National Defense Authorization Act for FY2024 (H.R. 2670, S. 2226).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE via CARDINAL POINT PARTNERS
2023 · fourth_quarter · Q4
Military healthcare issues in the National Defense Authorization Act for FY2024 (S. 2226, H.R. 2670)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SCIENTIFIC SYSTEMS COMPANY, INC. via CARDINAL POINT PARTNERS
2023 · third_quarter · Q3
Air Force research and development of navigation technologies and research and development on Navy unmanned aerial vehicles in the Defense Appropriations Act for FY2024 (H.R. 4365, S. 2587).
Filing targets: SENATE
ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE via CARDINAL POINT PARTNERS
2023 · third_quarter · Q3
Military healthcare issues in the National Defense Authorization Act for FY2024 (S. 2226, H.R. 2670)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TONIX PHARMACEUTICALS, INC. via CARDINAL POINT PARTNERS
2023 · third_quarter · Q3
Medical Countermeasures research, development and acquisition in the Pandemic All-Hazards Preparedness Act reauthorization (no bill numbers).
Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2024 (H.R. 4365, S. 2587)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERAL ELECTRIC COMPANY via CARDINAL POINT PARTNERS
2023 · third_quarter · Q3
Air Force research and development on manufacturing for aircraft sustainment and hypersonics in the National Defense Authorization Act for FY2024 (H.R. 2670, S. 2226).
Air Force research and development on manufacturing for aircraft sustainment and hypersonics in the Defense Appropriations Act for FY2024 (H.R. 4365, S. 2587).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE via CARDINAL POINT PARTNERS
2023 · second_quarter · Q2
Military healthcare issues in the National Defense Authorization Act for FY2024 (no bill numbers)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE via CARDINAL POINT PARTNERS
2023 · first_quarter · Q1
Military healthcare issues in the National Defense Authorization Act for FY2024 (no bill numbers)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SCIENTIFIC SYSTEMS COMPANY, INC. via CARDINAL POINT PARTNERS
2023 · second_quarter · Q2
Air Force research and development of navigation technologies and research and development on Navy unmanned aerial vehicles in the Defense Appropriations Act for FY2024 (H.R. 4365).
Air Force navigation systems research and development and Navy research and development of unmanned aerial vehicles in the National Defense Authorization Act for FY2024 (no bill numbers)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SCIENTIFIC SYSTEMS COMPANY, INC. via CARDINAL POINT PARTNERS
2023 · first_quarter · Q1
Air Force research and development of navigation technologies and research and development on Navy unmanned aerial vehicles in the Defense Appropriations Act for FY2024 (no bill numbers)
Air Force navigation systems research and development and Navy research and development of unmanned aerial vehicles in the National Defense Authorization Act for FY2024 (no bill numbers)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TONIX PHARMACEUTICALS, INC. via CARDINAL POINT PARTNERS
2023 · second_quarter · Q2
Biodefense medical countermeasures research and development in the National Defense Authorization Act for FY2024 (no bill numbers).
Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2024 (H.R. 4365)
Medical Countermeasures research, development and acquisition in the Pandemic All-Hazards Preparedness Act reauthorization (no bill numbers).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TONIX PHARMACEUTICALS, INC. via CARDINAL POINT PARTNERS
2023 · first_quarter · Q1
Medical Countermeasures research, development and acquisition in the Pandemic All-Hazards Preparedness Act reauthorization (no bill numbers).
Biodefense medical countermeasures research and development in the National Defense Authorization Act for FY2024 (no bill numbers).
Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2024 (no bill numbers)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERAL ELECTRIC COMPANY via CARDINAL POINT PARTNERS
2023 · second_quarter · Q2
Air Force research and development on manufacturing for aircraft sustainment and hypersonics in the Defense Appropriations Act for FY2024 (H.R. 4365).
Air Force research and development on manufacturing for aircraft sustainment and hypersonics in the National Defense Authorization Act for FY2024 (No bill numbers).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERAL ELECTRIC COMPANY via CARDINAL POINT PARTNERS
2023 · first_quarter · Q1
Air Force research and development on manufacturing for aircraft sustainment and hypersonics in the Defense Appropriations Act for FY2024 (no bill numbers).
Air Force research and development on manufacturing for aircraft sustainment and hypersonics in the National Defense Authorization Act for FY2024 (no bill numbers).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SCIENTIFIC SYSTEMS COMPANY, INC. via CARDINAL POINT PARTNERS
2022 · fourth_quarter · Q4
Air Force RDTE funding for navigation technologies in the National Defense Authorization Act for FY2023 H.R. 7900, S. 4543, H.R. 7776.
Air Force RDTE funding and Navy RDTE funding for aircraft navigation technologies in the Defense Appropriations Act for FY 2023 (H.R. 8236) and the Consolidated Appropriations Act, FY2023 (H.R. 2617).
Filing targets: SENATE
TONIX PHARMACEUTICALS, INC. via CARDINAL POINT PARTNERS
2022 · fourth_quarter · Q4
Advocating for expanded funding for advanced development of COVID vaccines in the Labor-HHS-Education Appropriations Act for FY 2023 (H.R. 8295) and the Consolidated Appropriations Act, FY2023 (H.R. 2617). Advocating for expanded funding for Defense Department research and development on biodefense vaccines in the Defense Appropriations Act for FY 2023 (H.R. 8236) and the Consolidated Appropriations Act, FY2023 (H.R. 2617).
Advocating for increased funding for research and development on biodefense vaccines in the National Defense Authorization Act for FY2023 (H.R. 7900, S. 4543, H.R. 7776)
ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE via CARDINAL POINT PARTNERS
2022 · fourth_quarter · Q4
Military healthcare issues in the National Defense Authorization Act, FY2023 (HR 7776)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERAL ELECTRIC COMPANY via CARDINAL POINT PARTNERS
2022 · fourth_quarter · Q4
Navy RDTE funding in the Defense Appropriations Act for FY 2023 (H.R. 8236)
Filing targets: HOUSE OF REPRESENTATIVES
ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE via CARDINAL POINT PARTNERS
2022 · third_quarter · Q3
Military healthcare issues in the National Defense Authorization Act, FY2023 (HR 7900, S.4543)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SCIENTIFIC SYSTEMS COMPANY, INC. via CARDINAL POINT PARTNERS
2022 · third_quarter · Q3
Air Force RDTE funding for navigation technologies in the National Defense Authorization Act for FY2023 (S. 4543).
Air Force RDTE funding and Navy RDTE funding for aircraft navigation technologies in the Defense Appropriations Act for FY 2023 (No Senate bill introduced)
Filing targets: SENATE
GENERAL ELECTRIC COMPANY via CARDINAL POINT PARTNERS
2022 · third_quarter · Q3
Navy RDTE funding in the Defense Appropriations Act for FY 2023 (H.R. 8236)
Filing targets: HOUSE OF REPRESENTATIVES
TONIX PHARMACEUTICALS, INC. via CARDINAL POINT PARTNERS
2022 · third_quarter · Q3
Proposed legislation on research and development into medical countermeasures for pandemic response and biosecurity under consideration by the Senate HELP (PREVENT Pandemics Act S.3799) House Energy and Commerce Committees (no bills introduced).
Advocating for expanded funding for advanced development of COVID vaccines in the Labor-HHS-Education Appropriations Act for FY 2023 (H.R. 8295) Advocating for expanded funding for Defense Department research and development on biodefense vaccines in the Defense Appropriations Act for FY 2023 (H.R. 8236).
Advocating for increased funding for research and development on biodefense vaccines in the National Defense Authorization Act for FY2023 (H.R. 7900, S. 4543).
TONIX PHARMACEUTICALS, INC. via CARDINAL POINT PARTNERS
2022 · second_quarter · Q2
Proposed legislation on research and development into medical countermeasures for pandemic response and biosecurity under consideration by the Senate HELP (PREVENT Pandemics Act S.3799) House Energy and Commerce Committees (no bills introduced).
Advocating for increased funding for research and development on biodefense vaccines in the National Defense Authorization Act for FY2023 (H.R. 7900).
Advocating for expanded funding for advanced development of COVID vaccines in the Labor-HHS-Education Appropriations Act for FY 2023 (H.R. 8295) Advocating for expanded funding for Defense Department research and development on biodefense vaccines in the Defense Appropriations Act for FY 2023 (H.R. 8236).
SCIENTIFIC SYSTEMS COMPANY, INC. via CARDINAL POINT PARTNERS
2022 · second_quarter · Q2
Air Force RDTE funding for navigation technologies in the National Defense Authorization Act for FY2023 (no bill introduced).
Air Force RDTE funding and Navy RDTE funding for aircraft navigation technologies in the Defense Appropriations Act for FY 2023 (H.R. 8236).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE via CARDINAL POINT PARTNERS
2022 · second_quarter · Q2
Military healthcare issues in the National Defense Authorization Act, FY2023 (HR 7900)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERAL ELECTRIC COMPANY via CARDINAL POINT PARTNERS
2022 · second_quarter · 2A
Promotion of federal government support for investment in small and medium sized business to develop additive manufacturing capabilities under the AM Forward program.
Filing targets: Executive Office of the President (EOP)
GENERAL ELECTRIC COMPANY via CARDINAL POINT PARTNERS
2022 · second_quarter · Q2
Promotion of federal government support for investment in small and medium sized business to develop additive manufacturing capabilities under the AM Forward program.
Filing targets: Executive Office of the President (EOP)
GENERAL ELECTRIC COMPANY via CARDINAL POINT PARTNERS
2022 · second_quarter · Q2
Promotion of federal government support for investment in small and medium sized business to develop additive manufacturing capabilities under the AM Forward program.
Filing targets: Executive Office of the President (EOP)
SCIENTIFIC SYSTEMS COMPANY, INC. via CARDINAL POINT PARTNERS
2022 · first_quarter · Q1
Air Force RDTE funding and Navy RDTE funding for aircraft navigation technologies in the Consolidated Appropriations Act for FY2022 (H.R. 4502) and the Defense Appropriations Act for FY 2023 (no bill introduced).
Air Force RDTE funding for navigation technologies in the National Defense Authorization Act for FY2022 (H.R. 4350) and the National Defense Authorization Act for FY2023 (no bill introduced).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERAL ELECTRIC COMPANY via CARDINAL POINT PARTNERS
2022 · first_quarter · Q1
Promotion of federal government support for investment in small and medium sized business to develop additive manufacturing capabilities under the AM Forward program. Advocating for effective support of US essential supply chain capabilities in the Defense Production Act (no bill introduced).
Air Force research and development and Defense-wide research and development in the Consolidated Appropriations Act for FY2022 (H.R. 4502)
Filing targets: Executive Office of the President (EOP), SENATE
TONIX PHARMACEUTICALS, INC. via CARDINAL POINT PARTNERS
2022 · first_quarter · Q1
Advocating for expanded funding for advanced development of COVID vaccines in Coronavirus Supplemental Appropriations Act (HR925) and the Labor-HHS-Education Appropriations Act for FY 2023 (H.R. 4502 and S. 3062) Advocating for expanded funding for Defense Department research and development on biodefense vaccines in the Defense Appropriations Act for FY 2023 (no bills introduced).
Advocating for increased funding for research and development on biodefense vaccines in the National Defense Authorization Act for FY2023 (No bills introduced).
Proposed legislation on research and development into medical countermeasures for pandemic response and biosecurity under consideration by the Senate HELP (PREVENT Pandemics Act S.3799) House Energy and Commerce Committees (no bills introduced).
ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE via CARDINAL POINT PARTNERS
2022 · first_quarter · Q1
Military healthcare issues in the National Defense Authorization Act, FY2023 (No bill yet introduced)
Filing targets: SENATE
SCIENTIFIC SYSTEMS COMPANY, INC. via CARDINAL POINT PARTNERS
2021 · fourth_quarter · Q4
Air Force RDTE funding and Navy RDTE funding for aircraft navigation technologies in the Department of Defense Appropriations Act, FY2022(H.R. 4432, S. 3023).
Air Force RDTE funding for navigation technologies in the National Defense Authorization Act for FY2022 (H.R. 4350 and S. 1605).
Filing targets: SENATE
SCIENTIFIC SYSTEMS COMPANY, INC. via CARDINAL POINT PARTNERS
2021 · third_quarter · Q3
Air Force RDTE funding and Navy RDTE funding for aircraft navigation technologies in the Department of Defense Appropriations Act, FY2022(H.R. 4432, S. 3023).
Air Force RDTE funding for navigation technologies in the National Defense Authorization Act for FY2022 (H.R. 4350 and S. 1605).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERAL ELECTRIC COMPANY via CARDINAL POINT PARTNERS
2021 · fourth_quarter · Q4
Air Force research and development and Defense-wide research and development in the Defense Appropriations Act for FY2022 (HR4432, S. 3023).
Promotion of federal government support for investment in small and medium sized business to develop additive manufacturing capabilities.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
TONIX PHARMACEUTICALS, INC. via CARDINAL POINT PARTNERS
2021 · fourth_quarter · Q4
Advocating for expanded funding for advanced development of COVID vaccines in Coronavirus Supplemental Appropriations Act (HR925) and the Labor-HHS-Education Appropriations Act for FY 2023 (H.R. 4502 and S. 3062)
Proposed legislation on research and development into medical countermeasures for pandemic response and biosecurity under consideration by the Senate HELP and House Energy and Commerce Committees (no bills introduced).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TONIX PHARMACEUTICALS, INC. via CARDINAL POINT PARTNERS
2021 · third_quarter · Q3
Proposed legislation on research and development into medical countermeasures for pandemic response and biosecurity under consideration by the Senate HELP and House Energy and Commerce Committees (no bills introduced).
Advocating for expanded funding for advanced development of COVID vaccines in Coronavirus Supplemental Appropriations Act (HR925) and the Labor-HHS-Education Appropriations Act for FY 2023 (H.R. 4502 and S. 3062)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE via CARDINAL POINT PARTNERS
2021 · fourth_quarter · Q4
Military healthcare issues in the National Defense Authorization Act, FY2022 (HR 4350, S. 2792)
Filing targets: SENATE
RF CHECK, INC via CARDINAL POINT PARTNERS
2021 · fourth_quarter · Q4
Issues related to workplace exposure to radio frequency emissions.
GENERAL ELECTRIC COMPANY via CARDINAL POINT PARTNERS
2021 · third_quarter · Q3
Air Force research and development in the Defense Appropriations Act for FY2022 (HR 4322) Defense-wide research and development in the Defense Appropriations Act for FY2022 (HR 4322)
Air Force research and development in the Defense Appropriations Act for FY2022 (HR 4322) Defense-wide research and development in the Defense Appropriations Act for FY2022 (HR 4322)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE via CARDINAL POINT PARTNERS
2021 · third_quarter · Q3
Military healthcare issues in the National Defense Authorization Act, FY2022 (HR 4350, S. 2792)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RF CHECK, INC via CARDINAL POINT PARTNERS
2021 · third_quarter · Q3
Issues related to workplace exposure to radio frequency emissions.
SCIENTIFIC SYSTEMS COMPANY, INC. via CARDINAL POINT PARTNERS
2021 · second_quarter · Q2
Air Force RDTE funding in the Department of Defense Appropriations Act, FY2022 (no bill number) Navy RDTE Funding in the Department of Defense Appropriations Act, FY2022 (no bill number)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TONIX PHARMACEUTICALS, INC. via CARDINAL POINT PARTNERS
2021 · second_quarter · Q2
Funding for pandemic response research and development (no bill)
Filing targets: HOUSE OF REPRESENTATIVES
ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE via CARDINAL POINT PARTNERS
2021 · second_quarter · Q2
Military healthcare issues in the National Defense Authorization Act, FY2022 (no bill number)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERAL ELECTRIC COMPANY via CARDINAL POINT PARTNERS
2021 · second_quarter · Q2
Air Force research and development in the Defense Appropriations Act for FY2022 (HR 4322) Defense-wide research and development in the Defense Appropriations Act for FY2022 (HR 4322)
Air Force research and development in the Defense Appropriations Act for FY2022 (HR 4322) Defense-wide research and development in the Defense Appropriations Act for FY2022 (HR 4322)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RF CHECK, INC via CARDINAL POINT PARTNERS
2021 · second_quarter · Q2
Issues related to workplace exposure to radio frequency emissions.
SCIENTIFIC SYSTEMS COMPANY, INC. via CARDINAL POINT PARTNERS
2021 · first_quarter · Q1
Air Force RDTE funding in the Department of Defense Appropriations Act, FY2022 (no bill number)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TONIX PHARMACEUTICALS, INC. via CARDINAL POINT PARTNERS
2021 · first_quarter · Q1
Funding for pandemic response research and development funding in HR 1219 The American Rescue Plan Act of 2021
Filing targets: SENATE
GENERAL ELECTRIC COMPANY via CARDINAL POINT PARTNERS
2021 · first_quarter · Q1
Air Force research and development in the Defense Appropriations Act for FY2022 (no bill number) Navy research and development in the Defense Appropriations Act for FY2022 (no bill number) Defense-wide research and development in the Defense Appropriations Act for FY2022
NASA research funding in the Commerce, Justice, Science and Related Agencies Appropriations Bill, FY2022 (no bill number)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE via CARDINAL POINT PARTNERS
2021 · first_quarter · Q1
Military healthcare issues in the National Defense Authorization Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RF CHECK, INC via CARDINAL POINT PARTNERS
2021 · first_quarter · Q1
Issues related to workplace exposure to radio frequency emissions.
SCIENTIFIC SYSTEMS COMPANY, INC. via CARDINAL POINT PARTNERS
2020 · fourth_quarter · Q4
Air Force and Navy RDT&E issues in Department of Defense Appropriations Bill for FY2021, H.R. 7617, Omnibus and COVID Relief and Response Act, H.R. 133
Filing targets: SENATE
ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE via CARDINAL POINT PARTNERS
2020 · fourth_quarter · Q4
Military healthcare in the National Defense Authorization Act for FY2021, H.R. 6395, S. 4049
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TONIX PHARMACEUTICALS, INC. via CARDINAL POINT PARTNERS
2020 · fourth_quarter · Q4
Pandemic preparedness and response funding in HR 7614, the Labor, HHS and Related Agencies Appropriations Act for FY 2021; Omnibus and COVID Relief and Response Act H.R. 133
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERAL ELECTRIC COMPANY via CARDINAL POINT PARTNERS
2020 · fourth_quarter · Q4
Army RDT&E issues in the Omnibus and COVID Relief and Response Act, H.R. 133
Filing targets: SENATE
RF CHECK, INC via CARDINAL POINT PARTNERS
2020 · fourth_quarter · Q4
Issues related to workplace exposure to radio frequency emissions.
SCIENTIFIC SYSTEMS COMPANY, INC. via CARDINAL POINT PARTNERS
2020 · third_quarter · Q3
Air Force and Navy RDT&E issues in Department of Defense Appropriations Bill for FY2021, H.R. 7617
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE via CARDINAL POINT PARTNERS
2020 · third_quarter · Q3
Military healthcare in the National Defense Authorization Act for FY2021, H.R. 6395, S. 4049
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERAL ELECTRIC COMPANY via CARDINAL POINT PARTNERS
2020 · third_quarter · 3A
Air Force RDT&E in the Defense Appropriations Act, FY2021, H.R. 7617
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TONIX PHARMACEUTICALS, INC. via CARDINAL POINT PARTNERS
2020 · third_quarter · Q3
Funding for medical technology research and development in S.785 - Commander John Scott Hannon Veterans Mental Health Care Improvement Act of 2019
Pandemic preparedness and response funding in HR 7614, the Labor, HHS and Related Agencies Appropriations Act for FY 2021;
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
RF CHECK, INC via CARDINAL POINT PARTNERS
2020 · third_quarter · Q3
Issues related to workplace exposure to radio frequency emissions.
GENERAL ELECTRIC COMPANY via CARDINAL POINT PARTNERS
2020 · second_quarter · Q2
Air Force RDT&E in the Defense Appropriations Act, FY2021, H.R. 7617
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
GENERAL ELECTRIC COMPANY via CARDINAL POINT PARTNERS
2020 · first_quarter · RR
Research and development on advanced manufacturing technology for defense applications
SCIENTIFIC SYSTEMS COMPANY, INC. via CARDINAL POINT PARTNERS
2020 · second_quarter · Q2
Air Force and Navy RDT&E issues in Department of Defense Appropriations Bill for FY2021, H.R. 7617
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TONIX PHARMACEUTICALS, INC. via CARDINAL POINT PARTNERS
2020 · second_quarter · Q2
Funding for medical technology research and development in S.785 - Commander John Scott Hannon Veterans Mental Health Care Improvement Act of 2019
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE via CARDINAL POINT PARTNERS
2020 · second_quarter · Q2
Military healthcare in the National Defense Authorization Act for FY2021, H.R. 6395, S. 4049
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RF CHECK, INC via CARDINAL POINT PARTNERS
2020 · second_quarter · Q2
Issues related to workplace exposure to radio frequency emissions.
SCIENTIFIC SYSTEMS COMPANY, INC. via CARDINAL POINT PARTNERS
2020 · first_quarter · Q1
Air Force and Navy RDT&E issues in upcoming Department of Defense Appropriations Bill for FY2021
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TONIX PHARMACEUTICALS, INC. via CARDINAL POINT PARTNERS
2020 · first_quarter · Q1
Funding for medical technology research and development in S.785 - Commander John Scott Hannon Veterans Mental Health Care Improvement Act of 2019
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE via CARDINAL POINT PARTNERS
2020 · first_quarter · Q1
Military healthcare in the upcoming National Defense Authorization Act for FY2021
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RF CHECK, INC via CARDINAL POINT PARTNERS
2020 · first_quarter · Q1
Issues related to workplace exposure to radio frequency emissions.
SCIENTIFIC SYSTEMS COMPANY, INC. via CARDINAL POINT PARTNERS
2019 · fourth_quarter · Q4
Air Force and Navy RDT&E issues in the Department of Defense Appropriations Bill, (HR 2968)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TONIX PHARMACEUTICALS, INC. via CARDINAL POINT PARTNERS
2019 · fourth_quarter · Q4
Military medical research and development in the National Defense Authorization Act for FY2020 (S. 1790 and HR 2500) and Defense Appropriations Bill for FY2020 (H.R. 2968)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE via CARDINAL POINT PARTNERS
2019 · fourth_quarter · Q4
Military healthcare in the National Defense Authorization Act for FY2020 (S. 1790 and H.R. 2500)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RF CHECK, INC via CARDINAL POINT PARTNERS
2019 · fourth_quarter · Q4
Issues related to workplace exposure to radio frequency emissions.
SCIENTIFIC SYSTEMS COMPANY, INC. via CARDINAL POINT PARTNERS
2019 · third_quarter · Q3
Air Force and Navy RDT&E issues in the Department of Defense Appropriations Bill, (HR 2968)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TONIX PHARMACEUTICALS, INC. via CARDINAL POINT PARTNERS
2019 · third_quarter · Q3
Military medical research and development in the National Defense Authorization Act for FY2020 (S. 1790 and HR 2500) and Defense Appropriations Bill for FY2020 (H.R. 2968)
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE via CARDINAL POINT PARTNERS
2019 · third_quarter · Q3
Military healthcare in the National Defense Authorization Act for FY2020 (S. 1790 and H.R. 2500)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RF CHECK, INC via CARDINAL POINT PARTNERS
2019 · third_quarter · Q3
Issues related to workplace exposure to radio frequency emissions.
SCIENTIFIC SYSTEMS COMPANY, INC. via CARDINAL POINT PARTNERS
2019 · second_quarter · Q2
Air Force and Navy RDT&E issues in the Department of Defense Appropriations Bill, (HR 2968)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SCIENTIFIC SYSTEMS COMPANY, INC. via CARDINAL POINT PARTNERS
2019 · first_quarter · Q1
Air Force and Navy RDT&E issues in the Department of Defense Appropriations Bill
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TONIX PHARMACEUTICALS, INC. via CARDINAL POINT PARTNERS
2019 · second_quarter · Q2
Military medical research and development in the National Defense Authorization Act for FY2020 (S. 1790 and HR 2500) and Defense Appropriations Bill for FY2020 (H.R. 2968)
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
ST. ELIZABETH'S MEDICAL CENTER - BRIGHTON MARINE via CARDINAL POINT PARTNERS
2019 · second_quarter · Q2
Military healthcare in the National Defense Authorization Act for FY2020 (S. 1790 and H.R. 2500)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Proposed legislation on research and development into medical countermeasures for pandemic response and biosecurity in the PREVENT Pandemics Act S.3799 and the FY2023 Consolidated Appropriations Act (H.R. 2617).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE